Viral Vector– tag –
-
ESC Congress 2026 Reveals Breakthrough Gene Therapies for Cardiovascular Disease: AAV8 Reduces LDL-C by 80-90%, siRNA Kylo-11 Achieves 97% Lp(a) Reduction
HCPLive (YouTube) USA Overview Groundbreaking data on multiple gene and molecular therapies for cardiovascular disease were presented at ESC Congress 2026. An AAV8-mediated gene therapy for homozygous familial hypercholesterolemia (HoFH)... -
Ocugen Doses First Patient in Phase 3 Registrational Trial for OCU410 Modifier Gene Therapy for Geographic Atrophy, Following RMAT Designation
GlobeNewswire USA Overview Ocugen has initiated patient dosing in its Phase 3 registrational trial for OCU410, a modifier gene therapy targeting geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). OCU410 rece... -
August Sees Mixed Fortunes in Gene Therapy: Ultragenyx’s GSDIa Therapy Gets Accelerated Approval, Epicrispr Raises $90M, While REGENXBIO’s RGX-121 Faces Clinical Hold
Vertex AI Search USA Overview August 2026 brought both significant advancements and setbacks in the next-generation therapeutics space. Ultragenyx secured FDA accelerated approval for GENGLYCOS, a gene therapy for GSDIa, offering a new o... -
4basebio and Genezen Partner to Revolutionize Viral Vector Manufacturing: hpDNA Boosts AAV Titers by up to 33-fold
AllSci Overview 4basebio and Genezen have announced a strategic collaboration to integrate 4basebio's hpDNA platform into viral vector manufacturing workflows, aiming to significantly enhance efficiency. This innovative cell-free synthet... -
4basebio and Genezen Partnership Revolutionizes Viral Vector Manufacturing: Cell-Free Synthetic DNA Reduces Costs by 30%
BioPharm International USA Overview 4basebio and viral vector CDMO Genezen announced a partnership to integrate 4basebio's cell-free hpDNA platform into Genezen's manufacturing workflow. This innovative technology enzymatically produces ... -
U.S. FDA Approves Pfizer and BioNTech’s XFG-Adapted COVID-19 Vaccine, Aligned with 2026 Fall Vaccination Guidance
Pfizer USA Overview Pfizer and BioNTech have received U.S. FDA approval for their XFG-adapted COVID-19 vaccine. This approval aligns with the FDA's guidance on the recommended composition for COVID-19 vaccines to be used in the United St... -
AusperBio Secures $120M Series C Funding to Advance Phase 3 for Chronic Hepatitis B ASO Therapy AHB-137 and Accelerate Au-HALO™ Platform’s HBV siRNA Development
BioSpace Global Overview AusperBio Therapeutics has successfully completed a $120 million Series C financing round to vigorously advance its lead antisense oligonucleotide (ASO) therapy, AHB-137, through Phase 3 enrollment and towards co... -
New Blood-Brain Barrier Penetration Strategies: Peptides and ‘Trojan Horse’ Approaches Revolutionize Brain Drug Delivery
Facebook USA Overview The blood-brain barrier (BBB) blocks approximately 95% of drugs, severely impeding treatment for brain disorders. Researchers are developing novel techniques to bypass this barrier, including 'Trojan horse' approach... -
FDA Approves First Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa), Offering New Option for Patients Aged 8+
Pharmacy Times USA Overview The U.S. FDA has approved the first gene therapy for Glycogen Storage Disease Type Ia (GSDIa), targeting the underlying cause of this rare metabolic disorder in patients aged 8 and older. GSDIa results from a ... -
Regenxbio’s Hunter Syndrome Gene Therapy Refiling Halted by Second FDA Clinical Hold
Fierce Biotech USA Overview Regenxbio's plan to refile its gene therapy for Hunter syndrome (MPS II) has been derailed by a clinical hold imposed by the FDA, leading the company to postpone its regulatory submission indefinitely. This ma...
